A Study to Evaluate the Safety, Efficacy, and Pharmacodynamics of PLL001 in ALS Patients

NCT06513546 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

153

Enrollment

INDUSTRY

Sponsor class

Conditions

Amyotrophic Lateral Sclerosis
ALS

Interventions

DRUG: PLL001 or placebo daily subcutaneous injections

Sponsor

PLL TX AUSTRALIA PTY LTD